# A Phase 2 Study to Evaluate Povetacicept in Adults With Generalized Myasthenia Gravis

> **NCT07501702** · PHASE2 · RECRUITING · sponsor: **Vertex Pharmaceuticals Incorporated** · enrollment: 30 (estimated)

## Conditions studied

- Myasthenia Gravis, Generalized

## Interventions

- **DRUG:** Povetacicept
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07501702
- **Lead sponsor:** Vertex Pharmaceuticals Incorporated
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-05
- **Primary completion:** 2029-03-02
- **Final completion:** 2029-03-02
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-05-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07501702

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07501702, "A Phase 2 Study to Evaluate Povetacicept in Adults With Generalized Myasthenia Gravis". Retrieved via AI Analytics 2026-05-21 from https://api.ai-analytics.org/clinical/NCT07501702. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*